
Sarepta Therapeutics, Inc. – NASDAQ:SRPT
Sarepta Therapeutics stock price today
Sarepta Therapeutics stock price monthly change
Sarepta Therapeutics stock price quarterly change
Sarepta Therapeutics stock price yearly change
Sarepta Therapeutics key metrics
Market Cap | 11.27B |
Enterprise value | 11.93B |
P/E | -16.72 |
EV/Sales | 12.79 |
EV/EBITDA | -19.37 |
Price/Sales | 12.11 |
Price/Book | 29.36 |
PEG ratio | 0.24 |
EPS | 0.13 |
Revenue | 1.40B |
EBITDA | -52.88M |
Income | 16.89M |
Revenue Q/Q | 63.10% |
Revenue Y/Y | 43.82% |
Profit margin | -75.4% |
Oper. margin | -57.47% |
Gross margin | 85% |
EBIT margin | -57.47% |
EBITDA margin | -3.77% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSarepta Therapeutics stock price history
Sarepta Therapeutics stock forecast
Sarepta Therapeutics financial statements
$185.78
Potential upside: 838.27%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 261.23M | -23.94M | -9.16% |
---|---|---|---|
Sep 2023 | 331.81M | -40.93M | -12.34% |
Dec 2023 | 396.78M | 45.65M | 11.51% |
Mar 2024 | 413.46M | 36.11M | 8.74% |
Jun 2023 | 3125890000 | 2.38B | 76.28% |
---|---|---|---|
Sep 2023 | 3109707000 | 2.34B | 75.42% |
Dec 2023 | 3264576000 | 2.40B | 73.68% |
Mar 2024 | 3224385000 | 2.26B | 70.19% |
Jun 2023 | -122.23M | 96.63M | 5.86M |
---|---|---|---|
Sep 2023 | -114.70M | -210.57M | 15.40M |
Dec 2023 | -54.65M | -64.35M | 1.94M |
Mar 2024 | -242.07M | 218.79M | 22.14M |
Sarepta Therapeutics alternative data
Aug 2023 | 1,162 |
---|---|
Sep 2023 | 1,162 |
Oct 2023 | 1,162 |
Nov 2023 | 1,162 |
Dec 2023 | 1,162 |
Jan 2024 | 1,162 |
Feb 2024 | 1,162 |
Mar 2024 | 1,314 |
Apr 2024 | 1,314 |
May 2024 | 1,314 |
Jun 2024 | 1,314 |
Jul 2024 | 1,314 |
Sarepta Therapeutics other data
Period | Buy | Sel |
---|---|---|
Mar 2024 | 0 | 24096 |
May 2024 | 0 | 3635 |
Jun 2024 | 0 | 50714 |
Aug 2024 | 37038 | 5985 |
Dec 2024 | 0 | 12136 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | WIGZELL HANS LENNART RUDOLF director | Common Stock | 10,500 | $13.71 | $143,955 | ||
Sale | WIGZELL HANS LENNART RUDOLF director | Common Stock | 10,500 | $124.84 | $1,310,820 | ||
Option | WIGZELL HANS LENNART RUDOLF director | Stock Options (right to buy) | 10,500 | $13.71 | $143,955 | ||
Sale | BOOR KATHRYN JEAN director | Common Stock | 1,636 | $125.55 | $205,400 | ||
Sale | ESTEPAN IAN MICHAEL officer: Chief Fi.. | Common Stock | 5,985 | $137.36 | $822,100 | ||
Purchase | CHAMBERS MICHAEL ANDREW director | Common Stock | 5,648 | $134.66 | $760,560 | ||
Purchase | CHAMBERS MICHAEL ANDREW director | Common Stock | 18,284 | $134.06 | $2,451,153 | ||
Purchase | CHAMBERS MICHAEL ANDREW director | Common Stock | 13,106 | $133.07 | $1,744,015 | ||
Option | BEHRENS M KATHLEEN director | Common Stock | 15,000 | $13.9 | $208,500 | ||
Option | BEHRENS M KATHLEEN director | Stock Option (right to buy) | 15,000 | $13.9 | $208,500 |
Patent |
---|
Grant Filling date: 30 Apr 2021 Issue date: 26 Jul 2022 |
Grant Utility: Processes for preparing oligomers Filling date: 16 Nov 2020 Issue date: 12 Jul 2022 |
Grant Filling date: 14 Dec 2017 Issue date: 12 Jul 2022 |
Grant Filling date: 24 Jul 2020 Issue date: 24 May 2022 |
Application Filling date: 15 Apr 2021 Issue date: 24 Mar 2022 |
Application Filling date: 21 Oct 2021 Issue date: 3 Feb 2022 |
Application Filling date: 17 Sep 2021 Issue date: 3 Feb 2022 |
Grant Filling date: 5 Sep 2014 Issue date: 1 Feb 2022 |
Application Filling date: 11 Jun 2021 Issue date: 20 Jan 2022 |
Grant Filling date: 20 May 2019 Issue date: 28 Dec 2021 |
Quarter | Transcript |
---|---|
Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
Sarepta: Finally, A Little Relief For Bulls; I Expect More
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months
Down To Levels Not Seen Since 2016: Initiating Sarepta With A Buy
Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity
Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom
Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
-
What's the price of Sarepta Therapeutics stock today?
One share of Sarepta Therapeutics stock can currently be purchased for approximately $19.8.
-
When is Sarepta Therapeutics's next earnings date?
Unfortunately, Sarepta Therapeutics's (SRPT) next earnings date is currently unknown.
-
Does Sarepta Therapeutics pay dividends?
No, Sarepta Therapeutics does not pay dividends.
-
How much money does Sarepta Therapeutics make?
Sarepta Therapeutics has a market capitalization of 11.27B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.26% to 1.24B US dollars.
-
What is Sarepta Therapeutics's stock symbol?
Sarepta Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SRPT".
-
What is Sarepta Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sarepta Therapeutics?
Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sarepta Therapeutics's key executives?
Sarepta Therapeutics's management team includes the following people:
- Mr. Douglas S. Ingram Pres, Chief Executive Officer & Director(age: 62, pay: $1,290,000)
- Dr. Gilmore O'Neill M.D. Executive Officer(age: 60, pay: $891,940)
- Dr. Louise Rodino-Klapac Ph.D. Chief Scientific Officer and Head of R&D(age: 47, pay: $739,050)
- Mr. Ian Michael Estepan Executive Vice President & Chief Financial Officer(age: 49, pay: $684,120)
- Mr. William F. Ciambrone Executive Vice President of Technical Operations(age: 61, pay: $679,940)
- Mr. Joseph Bratica Controller & Vice President(age: 61, pay: $438,510)
-
How many employees does Sarepta Therapeutics have?
As Jul 2024, Sarepta Therapeutics employs 1,314 workers.
-
When Sarepta Therapeutics went public?
Sarepta Therapeutics, Inc. is publicly traded company for more then 28 years since IPO on 4 Jun 1997.
-
What is Sarepta Therapeutics's official website?
The official website for Sarepta Therapeutics is sarepta.com.
-
Where are Sarepta Therapeutics's headquarters?
Sarepta Therapeutics is headquartered at 215 First Street, Cambridge, MA.
-
How can i contact Sarepta Therapeutics?
Sarepta Therapeutics's mailing address is 215 First Street, Cambridge, MA and company can be reached via phone at +61 72744000.
-
What is Sarepta Therapeutics stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Sarepta Therapeutics in the last 12 months, the avarage price target is $185.78. The average price target represents a 838.27% change from the last price of $19.8.
Sarepta Therapeutics company profile:

Sarepta Therapeutics, Inc.
sarepta.comNASDAQ
1,314
Biotechnology
Healthcare
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
CIK: 0000873303
ISIN: US8036071004
CUSIP: 803607100